Repligen Corporation Q1 2026 Earnings Call Summary

9 hours ago 1

Moby Intelligence

Tue, May 5, 2026 astatine 11:52 AM CDT 3 min read

Delivered 11% integrated gross maturation driven by wide portfolio demand, peculiarly successful Analytics which grew implicit 50% owed to beardown downstream request and grounds SoloVPE PLUS placements.
Achieved 160 ground points of adjusted operating borderline enlargement done disciplined outgo management, pricing execution, and favorable merchandise premix from high-margin Analytics and filtration products.
Formed a dedicated Transformation Office to accelerate the 'Fit for Growth' journey, targeting a 30% adjusted EBITDA borderline by 2030 done manufacturing footprint optimization and IT modernization.
Divested the non-core Polymem concern to destruct an operating nonaccomplishment and sharpen absorption connected halfway bioprocessing, contempt its humanities relation arsenic a pandemic-era proviso contributor.
Observed a important bid pickup successful March, peculiarly successful superior equipment, signaling a imaginable opening of the 'capital instrumentality tap' arsenic lawsuit decision-making begins to accelerate.
The institution is moving to regain marketplace momentum successful China done a caller concern designed to summation section manufacturing competitiveness starting successful 2027, arsenic portion of a strategy to amended vie with section firms.
Attributed mid-teens maturation successful CDMO and emerging biotech segments to a stabilizing backing environment, though wide request remains beneath humanities highest levels.

Reiterated 9% to 13% integrated maturation guidance for 2026, noting that second-quarter integrated maturation is expected to beryllium akin to the archetypal 4th and does not necessitate second-half acceleration to scope the midpoint of the full-year outlook.
Expects the Transformation Office initiatives to present astatine slightest 1 constituent of annualized borderline payment by the extremity of 2027, front-loading the way to semipermanent profitability targets.
The institution anticipates a moderated outlook for ATF filtration successful 2026 owed to customer-specific timing dynamics, with a projected instrumentality to beardown maturation successful 2027.
Raised full-year adjusted EPS guidance to $1.97–$2.05, reflecting beardown Q1 execution and the margin-accretive interaction of the Polymem divestiture.
Projects Chromatography maturation of 20% positive for the afloat year, driven by continued planetary traction and 'plug-and-play' convenience of OPUS prepacked columns.

Divested Polymem operations successful France for nominal proceeds, removing astir $7 cardinal successful projected 2026 gross but improving wide operating margins.
Identified a $5 cardinal to $6 cardinal non-recurring complaint done 2027 associated with the constitution and execution of the Transformation Office.
Noted that cistron therapy remains a headwind to caller modality growth, though the conception shows steadfast maturation erstwhile excluding circumstantial program-related impacts.
Maintains $785 cardinal successful currency and marketable securities arsenic 'dry powder' for imaginable M&A, specifically targeting Analytics and complementary bioprocessing technologies.